E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
- arterial compliance - insulin resistance - decreased sexual desire after menopause |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020112 |
E.1.2 | Term | Hirsutism |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001763 |
E.1.2 | Term | Alopecia reversible |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000496 |
E.1.2 | Term | Acne |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10059294 |
E.1.2 | Term | Oily skin |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028813 |
E.1.2 | Term | Nausea |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10040880 |
E.1.2 | Term | Skin irritation |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of this study is to determine the effect of postmenopausal transdermal testosterone in conjunction with HRT on the cardiovascular system by assessing insulin resistance and arterial compliance.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to determine the effect of postmenopausal transdermal testosterone in conjunction with HRT on libido by assessing sexual functioning.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria:
• healthy postmenopausal women • 45 to 70 years of age • on HRT and willing to continue the same HRT regimen for the next 6 months • are in a stable relationship which was started at least 6 months ago • continue on any concomitant medications without any change during the study • give informed consent.
|
|
E.4 | Principal exclusion criteria |
Exclusion Criteria:
• have dyspareunia • have received testosterone implants within the last 12 months or other androgen therapy within the last 6 months • have received any medications which may interfere with the study (SSRI, anti-androgens, PDE5 inhibitors, DHEA, SERMS) • have a significant psychiatric disorder • have a history of breast cancer • have diabetes, thromboembolic disorders, cardiovascular disease or any condition affecting carbohydrate metabolism, uncontrolled hypertension and uncontrolled hyperlipidaemia • are on tibolone (due to its androgenic effect).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary end points are the effects of testorone patches on arterial compliance and insulin resistance.
Arterial compliance will be studied by applanation tonometry of the radial artery before and after salbutamol inhalation and sublingual GTN administration. Endothelial function assessments will also be carried out using digital volume changes following reactive hyperaemia .
Insulin resistance will be studied by means of Oral Glucose Tolerance Tests. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Reasons for such discontinuation includes the development of a disease that may put the participants at risk if they were to continue. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |